GLS and neoplasm: In a separate study, inhibiting glutamine utilization by tumor cells enhanced antitumor T cell responses, and the combination of a GLS inhibitor, CB-839, with a glutamine antagonist, DRP-104, demonstrated a synergistic effect, enhancing the response to anti-PD1 checkpoint inhibitor therapy in Keap1 mutant lung tumors [145].